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ABSTRACT 
DNA and RNA aptamers are becoming increasingly popular as biotechnological tools 
and possible therapeutic molecules, as they can often match or surpass the binding affinity and 
specificity of antibodies for their target in a much smaller molecule that is often better suited 
to experimental conditions. Aminoglycoside antibiotics were among the first targets for 
aptamers due to their high natural affinity for RNA, binding to many different sequence and 
structural motifs, resulting in a "selective" affinity for RNA which is less than specific, yet not 
quite broad enough to qualify as nonspecific binding. This selective binding allows 
aminoglycosides to bind to aptamers selected against other ligands, potentially altering the 
behavior of aptamer constructs containing aptamers not specifically targeted towards 
aminoglycosides. A selective aptamer binding enhancement by neomycin and a smaller 
increase by tobramycin is reported here when two aptamers are joined together into Cis-
Linked Aptamers for Microanalytical Procedures (CLAMPs), even when the aptamers were 
not designed to bind aminoglycosides. This results in allosteric binding behavior in these 
CLAMPs, where selective binding by arninoglycosides increases the binding ability of one of 
the aptamers. This allostery may be the result of these aminoglycosides binding to a portion 
of the aptamer constructs that is distinct from the regulated aptamer, stabilizing the structure 
of that portion of the construct so it does not interfere with the folding and binding of the 
regulated aptamer. This restores higher binding in an aptamer construct in which additional 
sequence adds to folding options and interferes with aptamer binding. In this way; 
aminoglycosides may act as generic allosteric activators for many different aptamer 
Vlll 
constructs. 
CLAMPs can also be used to link different species of fluorescent mesoporous silica 
nanospheres. In this way the fluorescent nanospheres can form optical logic gates, where two 
species of nanosphere are bound close enough by the CLAMP to produce fluorescence 
resonance energy transfer (FRET), an unique output from the input of the two nano spheres. 
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CHAPTER 1: GENERAL INTRODUCTION 
Introduction 
RNA and DNA have long been known to specifically bind proteins and small 
molecules during cellular processes such as replication, transcription, and translation. Due to 
this highly interactive behavior of either form of oligonucleotide, it should be no surprise that 
nucleic acid sequences can be found and isolated that bind to a wide range of molecules and 
can be utilized in a variety of biotechnological applications. A specific sequence of RNA or 
DNA that binds a certain molecule with high specificity and high affinity is called an aptamer 
and frequently consists of between 30 and 50 nucleotides. Aptamers can be selected by an in 
vitro procedure in which a random sequence library of oligonucleotides is selected for binding 
to the desired target molecule through multiple rounds of binding to an affinity column, 
amplifying the binding sequences, and finally cloning and sequencing the resulting set of 
aptamer sequences (1, 2). This selection method is also called SELEX, or Systematic 
Evolution of Ligands by EXponential enrichment (2), and can be used with a variety of DNA, 
RNA, or modified oligonucleotide sequence libraries and experimental conditions to facilitate 
discovery of aptamers suited for use at different temperatures, buffers, or cellular conditions. 
Development of aptamer applications has progressed remarkably, with over 100 
published DNA, RNA, and modified RNA aptamer sequences to different small molecules and 
proteins in the past 10 years. Aptamers are currently being tested for therapeutic applications 
such as inhibiting NS3 protease of the hepatitis C virus (3) or inhibiting the human 
transcription factor NF-KB for control of inflammation (4, 5). An aptamer inhibitor of Platelet 
2 
Derived Growth Factor is currently being tested as a cancer treatment (6, 7). Promising new 
aptamer-based alternatives for inhibiting thrombin for anticoagulation and vascular disease 
therapy are also being tested ( 8-12). 
While aptamers directed at proteins are increasing in popularity as potential new 
therapeutic tools, aptamers specific for small molecules are better suited to detailed 
examinations of the behavior of aptamers. Small molecules are stable in a wider variety of 
conditions and do not require proper folding like proteins. Small molecule ligands are also 
often completely enclosed in the aptamer binding pocket (13-17), reducing possible 
interferences with other portions of a complex aptamer construct containing additional 
sequence elements. The exact structure of an aptamer sequence is difficult to predict until an 
X-ray crystal structure or NMR solution structure has been determined, especially with RNA, 
which has many possibilities for folding and tertiary interactions. Even after a crystal or 
solution structure has been determined, aptamers likely have other folded states in solution 
that remain unobserved, balanced in a dynamic folding equilibrium (18, 19). The existence of 
this folding equilibrium suggests that more valuable aptamer constructs could be designed if 
their binding and interactions were better understood. 
Aptamers are even more valuable as biotechnological tools when their binding ability is 
combined with additional functionalities. Two aptamer sequences can be combined into dual 
aptamer constructs such that the binding of one ligand may either increase or decrease binding 
of the second ligand. The in vitro selection method can be modified to directly select for 
aptamer constructs with the desired behavior, sometimes called an allosteric selection. An 
aptamer inhibitor of the DNA repair enzyme formamidopyrimidine glycosylase was selected in 
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this manner such that its inhibitory effects are reduced by neomycin binding (20). Work done 
with ribozymes, RNA molecules with a catalytic ability, demonstrate several regulation 
schemes that could be applied to aptamers. Allosteric selection successfully identified a 
ribozyme dependent upon a small molecule ligand for catalytic ability (21). Even without 
employing allosteric selection, regulated ribozymes can be created by rational modular design, 
where separate catalytic or ligand-binding sequences are joined by a linking sequence to form 
a ribozyme with a more complex behavior. In this manner, ribozymes have been constructed 
that are stimulated (22) or inhibited (23) by an effector molecule, or even dependent upon 
binding of two effector molecules for maximum catalysis (24). While this shows incredible 
potential for rationally designing regulated ribozymes and aptamers, not all designs are this 
successful. Often multiple ribozyme constructs are made, and only a few are regulated by 
their effector molecule (22, 25, 26). The linking region between catalytic or ligand binding 
domains appears to be essential to create successful regulation. To aid in modular rational 
design, an allosteric selection step can be performed after initial design to select for a linker 
that creates an effective, regulated ribozyme (26-28). 
While the only published allosteric aptamer was created using allosteric selection (20), 
we have begun to utilize a rational design strategy for engineering allosteric aptamers. This 
approach has shown some measure of success in designing allosteric ribozymes, so rational 
design may also be useful for creating regulated aptamers. 
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Thesis Organization 
Chapter 2 contains the journal article manuscript pertaining to the selective aptamer 
binding enhancement (generic allosteric activation) caused by aminoglycoside antibiotics. 
This paper is in preparation for submission to Biochemistry for publication. I will be the first 
author on this paper, and Marit Nilsen-Hamilton will be the second and only other author, 
being the principal investigator on this project. Chapter 3 details the efforts to date to utilize 
small molecule dual aptamer constructs for linking fluorescent silica nanospheres for use as a 
potential optical logic gate and data storage biotechnology. This project is a collaboration 
with Victor Lin's group in the Chemistry department ofISU, who proposed the project. 
General conclusions follow these two separate projects in Chapter 4. 
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CHAPTER 2: SELECTIVE APT AMER BINDING ENHANCEMENT BY 
AMINOGLYCOSIDES 
a paper to be submitted to Biochemistry 
Becky A. Stodola and Marit Nilsen-Hamilton 
Abstract 
Many aptamers have been selected towards aminoglycoside molecules due to their 
natural affinity for nucleic acids, but this may cause later problems of specificity due to their 
ability to bind many different sequence and structure motifs. Aminoglycoside binding of 
nucleic acids may be better described as selective binding due to the wide range of sequences 
recognized. Here we combine two RNA aptamer sequences into a single molecule to form 
Cis-Linked Aptamers for Microanalytical Procedures (CLAMPs). Several aminoglycosides 
are able to bind selectively to RNA CLAMPs that contain non-aminoglycoside directed 
aptamers and that influence the binding ability of aptamers in these constructs. We propose 
that aminoglycosides have an allosteric effect upon binding of these dual aptamer constructs 
to their ligands, increasing the binding of one aptamer by selectively binding other parts of the 
construct and removing them from the folding options in the dynamic folding equilibrium of 
these complex RNA molecules. 
Introduction 
Aminoglycoside antibiotics are popular molecular targets for aptamers due to their 
high affinity for binding RNA and DNA and potential use as therapeutic treatments utilizing 
aptamer inhibitors. The high nucleic acid binding potential of aminoglycoside molecules is 
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apparent from the many different sequences and structures recognized by aminoglycosides 
such as neomycin, tobramycin, and kanamycin. Natural RNA sequences that aminoglycosides 
bind specifically include the A site of ribosomal 16S rRNA (29-35), HIV regions TAR (36) 
and RRE (37), the 5' untranslated region ofthymidylate synthase mRNA (38), tRNAAsP(l9), 
tRNAPhe (39), and a splicing regulatory element in exon 10 of the tau protein (40). 
Tobramycin has even been shown to bind to a polymeric designed oligonucleotide with a 
poly(rl)poly(rC) sequence ( 41). Although binding of aminoglycosides to a certain nucleic acid 
sequence is often reported as specific binding, the wide range of sequences recognized 
suggests that overall this would be better described as selective binding, where many different 
sequences form possible binding sites. 
Although most studies have focused on the binding properties of specific RNA 
sequences for aminoglycosides, it appears that the RNA structure is more important than the 
nucleic acid sequence (38). Many of the RNA sequences that aminoglycosides bind involve 
distorted helical regions, including internal bulges (35-38, 42), mismatch nucleotide pairs (37, 
43, 44), and short stem loop structures ( 40, 42, 44, 45). Many selected RNA aptamer 
sequences also form stem loop structures, including aminoglycoside aptamers (35, 43, 45-47). 
Some researchers even suggest that a non-A form RNA structure may be sufficient to bestow 
aminoglycoside binding ( 42, 47). 
Aminoglycosides have been shown to stabilize triplex RNA and DNA ( 48) and 
enhance thermal stability of the A site of 16S rRNA (34). The inhibitory effects of 
aminoglycosides on functional RNA are often believed to be due to distortions caused by their 
binding (30, 31, 36, 49). Aminoglycosides are also known to displace metal ions upon 
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binding of several RNA sequences (39, 50, 51). Small RNA molecules such as aptamers are 
proposed to have multiple stable structures, which likely exist in a dynamic folding 
equilibrium, where any given RNA molecule will shift between these stable structures. If 
aminoglycosides bind and stabilize a minor structural form, they shift this dynamic folding 
equilibrium towards the stabilized structure ( 18, 19). 
Aminoglycosides can affect the structure and function of RNA aptamers such that 
binding to the target molecule is reduced by an aminoglycoside such as neomycin (20). An 
allosteric selection procedure was used to select this regulated aptamer sequence, and 
kanamycin did not cause the same effect, so this appears to be a specific allosteric effect. 
However, when aminoglycosides are used the specificity of these effects may still be 
questionable due to their high natural affinity for nucleic acids. A higher concentration of an 
alternate aminoglycoside may cause the same effect as the specified ligand, so claims of 
specificity must be examined carefully. 
Here it is reported that aminoglycosides can produce an allosteric binding effect in 
rationally designed Cis-Linked Aptamers for Microanalytical Procedures (CLAMPs) that 
contain two aptamer sequences in a single RNA molecule. In these CLAMPs, binding of an 
aminoglycoside increases the binding ability of one of the aptamers. This increase in aptamer 
binding was shown to occur with dual aptamer constructs that contained various aptamer 
pairs and linkers, even when there was no aminoglycoside aptamer present. The binding of a 
single aptamer to its target is not influenced in this manner, so we believe the aminoglycosides 
act upon the additional sequence not already involved in specific binding to its ligand. We 
propose that the aminoglycosides bind selectively to this extra RNA segment, stabilizing its 
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structure, and allowing it less freedom to interfere with folding of the binding aptamer, thus 
increasing the binding ability of the aptamer. The aminoglycosides neomycin and tobramycin 
were both shown to produce this effect although the neomycin effect was larger than for 
tobramycin. This may suggest the use of aminoglycoside antibiotics to aid in folding and 
ligand binding of larger aptamer constructs containing more than a single aptamer sequence. 
This does complicate working with aminoglycoside aptamers, since binding behaviors are 
likely to be a complex mixture of specific and selective binding effects. 
Materials and Methods 
Materials. Neomycin, tobramycin, adenosine-5'-triphosphate (ATP), and theophylline 
were purchased from Sigma. Tris base, sodium chloride, and magnesium chloride were 
purchased from Fisher Scientific. 
RNA aptamer and CLAMP sample preparation. RNA secondary structures were 
predicted by the Mfold program (52, 53). Linear DNA templates and primer oligos were 
designed containing a T7 promoter before the aptamer or CLAMP sequence and were 
synthesized by the DNA Sequencing and Synthesis Facility oflowa State University. DNA 
templates were PCR amplified on a PTC-150 Mini Thermal Cycler (MJ Research) using Taq 
DNA polymerase (Promega) and deoxynucleotide triphosphates (MBI Fermentas). The 
double stranded DNA templates for the RNA aptamers and constructs were transcribed using 
T7 RNA polymerase and ribonucleotides (Promega), RNaseOUT ribonucleotide inhibitor 
(lnvitrogen), and [a32P]rCTP (ICN). An AmpliScribe T7 Transcription Kit (Epicentre 
Technologies) was used according to manufacturer's instructions for high yield production of 
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RNA for equilibrium dialysis. Aptamers and CLAMPs were purified using BioSpin 30 
Chromatography Columns (BioRad) to remove free NTPs. 
Column affinity aptamer binding assay. ATP agarose with a C8 linkage (Sigma) was 
used to measure ATP binding. Cyanogen bromide activated sepharose (Pharmacia Biotech) 
was linked to the amino groups of neomycin to produce an affinity matrix to measure 
neomycin binding. Following manufacturer's instructions for preparation of the sepharose, lg 
dry gel powder was swollen and coupled in a lmM neomycin solution at pH 7.6 to obtain 
approximately 2 umole neomycin coupled per 1 mL of gel. Remaining active groups were 
then blocked by a secondary coupling with a 0.2M glycine solution. 
Affinity column binding experiments were performed using empty micro biospin 
columns (BioRad) containing approximately 1 OOul of affinity matrix. The column was washed 
with 10 column volumes (lmL) of buffer A (50mM Tris, 250mM NaCl, 5mM MgCl2, pH 7.6 
at 23°C) before loading 32P-labeled aptamer or CLAMP in buffer A. After the radiolabeled 
RNA sample was added to the column, the column was washed with 20 column volumes 
(2mL) of buffer A, then the bound aptamer was eluted with 10 column volumes (lmL) of 
buffer A containing 1 OmM of the ligand. Wash and elution fractions were measured by 
scintillation or Cerenkov spectroscopy. When Cerenkov spectroscopy was used, the affinity 
matrix was also counted to check for aptamer that remained bound to the column after the 
RNA was eluted with the ligand. 
Gel mobility shift aptamer binding assay. 32P-labeled CLAMPs were mixed with ATP 
agarose at 23°C then resolved by 12% native polyacrylamide gels in TBE buffer (89mM Tris, 
89 mM boric acid, 2 mM EDTA, pH 8.5 at 23°C) to separate the bound from the unbound 
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CLAMPs. Gels were dried and the bands of unbound CLAMP were imaged and quantified by 
a Model 400A Phosphorlmager (Molecular Dynamics). 
Equilibrium dialysis assay. Equilibrium dialysis experiments utilized Equilibrium 
Dialyzers and 5kDa regenerated cellulose membranes (Nest Group). CLAMPs are between 
65 and 83 nucleotides in length and should not be able to pass the membrane while the 
radiolabeled ATP can equilibrate across the membrane. One chamber of each dialyzer 
contained buffer A, CLAMP, and the variable ligand, and the other chamber contained buffer 
A, [ y32P]ATP (ICN), and the variable ligand. The concentration of the ligand was varied in 
the different dialyzers to produce data for the effect of a gradient of ligand concentrations. 
The dialyzers were allowed to equilibrate overnight, and then samples were removed from 
each side of the membrane for ATP concentration measurement by scintillation spectroscopy. 
The percentage of ATP bound CLAMP was calculated from the ATP distribution across the 
chambers. 
Tl cleavage protection assay. Samples ofTheophylline-ATP CLAMP 613 were 
prepared with or without lmM theophylline. From 0 to 0.05U/ul ofribonuclease-T1 
(Calbiochem) were added to the samples immediately before loading and running at 23°C on a 
native 20% polyacrylamide gel in TBE buffer (89mM Tris, 89 mM boric acid, 2 mM EDT A, 
pH 8.5). The CLAMP was exposed to the ribonuclease for 5 min before loading on the gel. 
Gels were dried and the bands of RNA fragments were then imaged and quantified by a Model 
400A Phosphorlmager (Molecular Dynamics). The cleavage patterns were compared to 
determine cleavage protection by theophylline aptamer binding. 
Significance of all results were determined using a critical double tailed t test for all 
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values of p reported, calculated with a certainty of 95%. 
Results and Discussion 
RNA Neomycin/ ATP dual aptamer CLAMPs were designed using a neomycin binding 
sequence (44) and an ATP binding sequence (14, 54) (Table I). The two ligands have very 
different structures (Figure I), so binding of the opposite ligand should be minimized. The 
most stable predicted secondary structure of each of these aptamers (Figure 2a & c) resembles 
the published tertiary structures. CLAMPs were made with the two aptamers in either order 
with two uracil nucleotides as a linker, and also neomycin 5' to ATP 3' with a ten uracil linker 
(Table I). Both aptamers are predicted to fold independently as the separate aptamers (Figure 
2) when separated by two uracil nucleotides in the CLAMPs (Figures 3a & 4a), where they 
could not in constructs without the linker. The CLAMP with the ten uracil linker was 
produced to test the effect of a larger separation between the aptamers on their binding 
behavior. For each of these CLAMPs, there are at least 15 possible stable secondary 
structures (Figures 3 & 4) predicted by Mfold (52, 53), so a population of RNA molecules are 
likely to form a variety of conformations at any given time, where any one molecule can 
switch between stable structures. 
In the Neomycin/ ATP CLAMPs, the presence of neomycin increased the binding 
ability of the ATP aptamer end. This was shown using column affinity experiments (Figure 5), 
where the overall activity of the RNA preparations varied, but the ATP binding always 
increased when lmM neomycin was present. Gel binding assays (Figure 6) were also used to 
examine the effect of varied neomycin concentrations on ATP binding by the Neomycin-uu-
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ATP CLAMP 609 and ATP-uu-Neomycin CLAMP 610. From these gel binding assays, the 
enhancement of ATP binding is seen to be concentration dependent, with some increase in 
ATP binding seen with 1 OOuM or even 1 OuM neomycin. There was a logarithmic relationship 
between the neomycin concentration and the ATP binding. While this method is valuable for 
comparing many samples and conditions, measuring the unbound CLAMP in this way did not 
indicate how much of the CLAMP was bound to the ATP-agarose, which would be a more 
valuable measurement. There also appeared to be more error in gel binding data than when 
using column affinity. For example, in Figure 6a, the data points at a lmM neomycin 
concentration appear to be erroneous for both bands of unbound CLAMP in the gel. 
While the most commonly used assay for testing aptamer binding is affinity 
chromatography, and gel binding has also proven useful, both of these assays involve a solid 
phase of some kind to which the aptamer must bind or move through. Equilibrium dialysis 
was used to test the binding of the allosteric CLAMPs in solution (Figure 7). This method 
was surprisingly difficult to use for testing aptamer binding because it required large amounts 
of RNA and returned high errors. With some effort, however, data was obtained which 
supports the increase in ATP binding caused by the binding of neomycin (Figure 7). This data 
shows ATP binding to be about doubled with 120uM neomycin, which is about 10 times the 
RNA concentration, still a relatively low concentration to be producing this effect. 
RNA theophylline/ ATP CLAMPs were designed with a theophylline binding sequence 
(16, 55) 5' to an ATP binding sequence (14, 54), with (CLAMP 614) or without (CLAMP 
613) 10 uracil nucleotides as a linker between the two aptamers (Table 1). The structures of 
theophylline and ATP (Figure 8) are different enough to reduce the possibility of binding the 
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opposite ligand. Mfold secondary structure predictions (52, 53) return over 20 possible 
conformations for each CLAMP, consistent with the expected conformational flexibility and 
dynamic folding properties of small RNA molecules. The most stable structure for each 
construct resembles the structures of the single aptamers joined together (Figure 9), much like 
the neomycin/ ATP CLAMPs. 
The addition of lmM neomycin to the affinity column binding buffer increased the 
ATP binding of RNA theophylline/ ATP CLAMPs 613 and 614 (Figures 10 & 11 ). The 
presence of tobramycin also had a small effect. The same concentrations of neomycin or 
tobramycin did not affect the binding of the RNA ATP aptamer sequence by itself (Figure 12). 
This suggests that these aminoglycosides may act only upon the sequence 5' to the ATP 
aptamer end. In the CLAMPs, the presence or absence of the 10 uracil linker does not appear 
to change this increase in ATP binding due to aminoglycosides. These results suggest that the 
site of aminoglycoside binding is either the theophylline aptamer or the extra sequence in the 
CLAMP beyond the ATP aptamer. The theophylline aptamer contains structural motifs 
known to have aminoglycoside binding properties, a stem loop (35, 43, 45-47) and an internal 
bulge (35-38, 42), so it is no surprise that neomycin (and perhaps tobramycin) can bind to this 
end of the CLAMP. It is interesting to note that aminoglycosides increased the percentage of 
binding CLAMP (Figures 10 & 11) to a level closer to the original binding of the RNA ATP 
aptamer (Figure 12). This argues that the aminoglycosides restore ATP binding ability that 
was lost by the ATP aptamer when it was incorporated into the CLAMP. The additional 
nucleic acid sequence in the CLAMP may interfere with the proper folding of the ATP 
aptamer. 
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Because aminoglycosides may increase ATP binding by stabilizing the structure of the 
second aptamer in the CLAMP, it may be expected that theophylline will also stabilize its 
aptamer, and thereby increase ATP binding. However, this does not appear to be the case. In 
column affinity experiments lmM theophylline did not affect the ATP binding of the 
Theophylline-ATP CLAMP 613 (Figure 10) or the Theophylline-lOu-ATP CLAMP 614 
(Figure I la). The Theophylline-lOu-ATP CLAMP 614 affinity column binding data show a 
possible slight decrease in ATP binding upon lmM theophylline addition (Figure I la, double 
tailed t test, p = 0.03). However, in equilibrium dialysis experiments theophylline did not 
affect the ATP binding ability of either Theophylline-ATP CLAMP 613 or Theophylline-1 Ou-
ATP CLAMP 614 (Figure 13). Together, these results do not support the conclusion that 
theophylline alters ATP binding activity in the CLAMPs. 
With no present access to a theophylline affinity matrix, determining that theophylline 
is actually binding to the Theophylline/ ATP CLAMPs is difficult. The proper theophylline 
aptamer sequence (16, 55) is present in the sequence, and Mfold (52, 53) predicts that it 
should fold as required for binding its ligand, but still there may be some interference that 
prevents theophylline binding. To support our assumption oftheophylline binding, 
ribonuclease-T 1 cleavage assays were performed to test for cleavage protection provided by 
theophylline binding. There are several changes in the band intensity patterns between the 
samples with or without theophylline (Figure 14). Quantification of the band intensity 
changes showed that the overall trend upon addition of theophylline was an increase in the 
more slowly migrating RNA fragments and a decrease in the more rapidly migrating RNA 
fragments (Table 2), indicating that theophylline bestowed partial protection from T, cleavage. 
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This supports our assumption oftheophylline binding to the Theophylline-ATP CLAMP 613. 
Once a theophylline affinity matrix can be obtained, affinity column experiments will be 
performed to test for theophylline binding. 
The effect of neomycin and tobramycin on the Neomycin/ ATP and Theophylline/ ATP 
CLAMPs appears to be an allosteric enhancement of ATP binding ability caused by the 
selective binding of aminoglycosides. We propose that when the aminoglycosides bind to the 
neomycin or theophylline aptamer, the aptamer structure is stabilized (Figure I a & b ), 
potentially reducing its interference with the ATP aptamer end of the CLAMP. This 
decreases the fraction of CLAMP in states with misfolding of the ATP aptamer, such as the 
structures shown in Figure 2d & e for Neomycin-uu-ATP CLAMP 609. Thus, 
aminoglycoside binding is proposed to shift the dynamic folding equilibrium towards 
conformational states where the ATP aptamer is properly folded for binding, such as the 
structure shown in Figure 2a for Neomycin-uu-ATP CLAMP 609. This shift in the folding 
equilibrium would explain the increase in the overall ATP binding of the CLAMP. In this way 
the aminoglycosides perform a chaperone role in aiding proper folding of the ATP aptamer 
within the CLAMPs. 
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Table 1: RNA Aptamers and CLAMP Design3 
Aptamer I CLAMP Name 
Sequence 
Number 
Neomycin Aptamer ( 44) 
ggccugggcgagaaguuuaggcc 
Theophylline Aptamer (16, 55) 
ggcgauaccagccgaaaggcccuuggcagcguc 
601 
603 
ATP Aptamer ( 14, 54) 605 
ggguugggaagaaacuguggcacuucggugccagcaaccc 
Neomycin-uu-ATP CLAMP 609 
ggccugggcgagaaguuuaggcc uu ggguugggaagaaacuguggcacuucggugccagcaaccc 
ATP-uu-Neomycin CLAMP 610 
ggguugggaagaaacuguggcacuucggugccagcaaccc uu ggccugggcgagaaguuuaggcc 
Neomycin-IOu-ATP CLAMP 612 
ggccugggcgagaaguuuaggcc uuuuuuuuuu ggguugggaagaaacuguggcacuucggugccagcaaccc 
Theophylline-A TP CLAMP 613 
ggcgauaccagccgaaaggcccuuggcagcgucggguugggaagaaacuguggcacuucggugccagcaaccc 
Theophylline-lOu-ATP CLAMP 614 
ggcgauaccagccgaaaggcccuuggcagcguc uuuuuuuuuu 
ggguugggaagaaacuguggcacuucggugccagcaaccc 
a Linkers are underlined 
(a) 
(b) 
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Figure 1: Neomycin and ATP structures. The structures of 
(a) neomycin and (b) adenosine 5'-triphosphate (ATP) are shown. 
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Figure 2: Predicted dominant 
secondary structures for single 
aptamers. These are the most stable 
predicted secondary structures and their 
dGs for the aptamers used in CLAMP 
design. The (a) neomycin aptamer has 
one other, less stable, predicted 
structure, the (b) theophylline aptamer 
has 9 total, and the ( c) ATP aptamer 
has 15 total . 
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(a) (b) 
(c) 
Figure 3: Multiple possible secondary structures of Neomycin-uu-
ATP CLAMP 609. There are 15 secondary structures predicted for 
this CLAMP. The 5 structures and dGs shown are the (a) first and (b) 
second most stable structures and ( c) - ( e) a sampling of the other 
predicted secondary structures. Linkers are underlined. 
(b) 
20 
Figure 4: The most stable predicted secondary structure of (a) 
ATP-nu-Neomycin CLAMP 610 and (b) Neomycin-too-ATP 
CLAMP 612. The most stable structure and its dG is shown out 
of 19 predicted for ATP-uu-Neomycin CLAMP 610 and over 20 
predicted forNeomycin-lOu-ATP CLAMP 612. Linkers are 
underlined. 
60 
'O 50 c 
:::l 
D 
CD 40 L.. 
QJ 
E 
ro 
+-' 30 0.. 
<( 
'I-
D 
+-' 20 c 
QJ 
u 
L.. 
Q.) a.. 10 
0 
21 
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II No Neomycin 
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Figure 5: Neomycin increases ATP binding of 
Neomycin/ ATP CLAMPs. The addition of 
lmM neomycin to affinity column binding 
conditions approximately doubles the ATP 
binding of Neomycin-uu-ATP CLAMP 609 and 
Neomycin-lOu-ATP CLAMP 612 (177%-323% 
of original ATP binding seen when neomycin is 
added). Separate trials are shown. 
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Figure 6: Neomycin 
increases ATP binding 
of Neomycin/ATP 
CLAMPs in gel 
mobility shift assays. A 
range of neomycin 
concentrations were 
added to 10 pmol RNA 
samples of (a) 
Neomycin-uu-ATP 
CLAMP 609 or (b) 
ATP-uu-Neomycin 
CLAMP 610. ATP 
agarose was added to 
retain ATP-bound 
CLAMP in the wells, and 
the samples were run on 
native acrylamide gels. 
Bands of CLAMP not 
bound to the ATP 
agarose were quantified 
and compared. (a) is 
representative of two 
separate experiments. 
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Figure 7: Neomycin increases ATP binding of 
Neomycin-lOu-ATP CLAMP 612 in solution by 
equilibrium dialysis. CLAMP 612 at 13 .4 uM 
was incubated for 22 hours with 0-120 uM 
neomycin and o:32P-ATP. The distribution of 
o:32P-ATP was measured between the RNA and 
buffer chambers, and the binding of the CLAMP 
determined from this difference. 
(a) 
(c) 
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0 
Figure 8: Theophylline, ATP, and aminoglycoside structures. 
Structures of the CLAMP ligands (a) theophylline and (b) 
adenosine 5'-triphosphate (ATP), and aminoglycosides (c) 
neomycin B and ( d) tobramycin are shown. 
25 
Figure 9: The most stable predicted secondary structures of (a) 
Theophylline-ATP CLAMP 613 and (b) Theophylline-lOu-ATP 
CLAMP 614. The most stable structure and its dG is shown out of 
over 20 predicted for each CLAMP. The linker in (b) is underlined. 
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Figure 10: Aminoglycosides, but not theophylline, increase ATP binding of 
Theophylline-ATP CLAMP 613. Neomycin or tobramycin at lmM increase 
the ATP binding ability of Theophylline-A TP CLAMP 613, with no linker 
between the aptamers (neomycin: p < 0.0005; tobramycin: p < 0.05). 
Theophylline does not influence the ATP binding ofthis CLAMP (p = 0.85). 
Affinity column binding data is represented, n=6 for control, n=4 for other 
conditions. 
(a) 
70 
60 
Ol c: 50 '5 c: 
iD 40 o._ 
I-
<( 
30 ...... c w 
u ..__ 
20 (lJ o._ 
10 
0 
27 
(b) 
Theophylline-10u-ATP CLAMP 614 Theophylline-10u-ATP CLAMP 614 
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Figure 11: Aminoglycosides increase ATP binding of Theophylline-
10u-A TP CLAMP 614, and theophylline may decrease ATP 
binding slightly. (a) Neomycin or tobramycin at lmM increase the 
ATP binding ability of Theophylline-1 Ou-ATP CLAMP 614, with a 10 
uracil linker between the aptamers (not significant for this set of data, 
tobramycin: p = 0.21 ). Theophylline shows a slightly significant 
reduction in ATP binding (p = 0.03). (b) With a different RNA 
preparation, overall ATP binding is lower, but neomycin and tobramycin 
also increase ATP binding ability (neomycin: p < 0.02, tobramycin: p < 
0.07). Affinity column binding data is represented, (a) n=6 for control, 
n=4 for theophylline, n= 1 for neomycin, and n=2 for tobramycin, (b) 
n=2 for control, n=6 for neomycin, and n=2 for tobramycin. 
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RNA ATP Aptamer 605 
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Figure 12: Aminoglycosides do not increase 
ATP binding of the RNA ATP aptamer 605 
alone. Binding of the ATP aptamer used in the 
Theophylline/ ATP CLAMPs 613 & 614 is not 
affected by lrnM neomycin or tobramycin 
(neomycin: p = 0.88, tobramycin: p = 0.39). 
Affinity column binding data is represented, n=4 
for all conditions. 
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Figure 13: Theophylline does not affect ATP 
binding of Theophylline/ATP CLAMPs in solution 
as measured by equilibrium dialysis. Theophylline-
A TP CLAMP 613 or Theophylline-lOu-ATP CLAMP 
614 at l 5uM was incubated for 22 hours with O- l .2rnM 
theophylline and a32P-ATP. The distribution of 
a32P-ATP was measured between the RNA and buffer 
chambers, and the binding of the CLAMP determined. 
Results shown are representative of two separate 
experiments. 
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No Theophytline 1 mM Theophytline 
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Figure 14: Theophylline-ATP CLAMP 613 is partially protected from T 1 cleavage 
by theophylline. Various concentrations of ribonuclease-T 1 were incubated for 5 minutes 
with 50pmol (5uM) of uniformly 32P-labeled Theophylline-ATP CLAMP 613, with or 
without 1 mM theophylline. The samples were then immediately run on a 20% native 
polyacrylamide gel. The bands labeled A-F were quantified (see Table 2) in the 0.01 and 
0.001 U/ul samples and compared to see the protection caused by theophylline binding. 
31 
Table 2: Quantified Bands from T 1 Cleavage Protection in Figure 12. 
T 
0.01 
0.01 
0.01 
0.01 
0.01 
0.01 
0.001 
0.001 
Band Intensi 
A 9.00E+06 
B 2.93E+07 
C 7.94E+07 
D 3.34E+08 
E 1.33E+08 
F l.27E+08 
A 1.43E+o8 
B l.85E+08 
0.01 A 4.49E+07 
0.01 B l.30E+08 
0.01 C 2.80E+08 
0.01 D l.83E+08 
0.01 E 2.65E+07 
0.01 F 5.32E+07 
0.001 A 3.02E+08 
0.001 B 3.16E+08 
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Conclusion 
The ability of aminoglycosides to bind to RNA constructs containing aptamer 
sequences and influence the aptamer activity provides great opportunities for the rational 
design of allosteric aptamer constructs. As aminoglycoside binding motifs become more 
clearly recognizable, it will be easier to attach a binding sequence to the desired aptamer, 
potentially creating an aptamer with modifiable binding to its ligand without requiring an 
allosteric selection. Tunable aptamers could be very useful as therapeutic or diagnostic 
molecules, with primary ligand binding under control of a separate ligand. Aminoglycosides 
may even act as chaperones for RNA folding, opening up new applications for 
aminoglycosides when combined with RNA therapies or detection assays. 
However, the fact that the aminoglycosides can affect the activity of aptamer 
constructs intended for binding totally different ligands suggests possible problems in using 
aminoglycosides in aptamer applications. There may be effects from selective binding of the 
aminoglycosides when only specific aptamer-ligand binding was desired. Overall, the wide 
range of applications for using aminoglycosides to affect aptamer binding should compensate 
for the difficulty in controlling the selective binding effects of these versatile molecules. 
33 
CHAPTER 3: APTAMER LINKING OF FLUORESCENT SILICA NANOSPHERES 
Abstract 
Nucleic acid aptamers have the potential to become a valuable tool for numerous 
biotechnological applications. Aptamers can rival antibodies for specificity and affinity to 
their target ligand, yet are much smaller and more easily manipulated for various applications 
in vitro or in vivo. Aptamers are ideal for use in combination with mesoporous silica 
nanospheres, which can be designed with multiple fluorophores contained within and with 
various ligands attached covalently to the outside surface or the pore surfaces within the 
spheres. In this manner dual aptamer constructs, also called Cis-Linked Aptamers for 
Microanalytical Procedures (CLAMPs), can be used to bind two species of fluorescent silica 
nanospheres together. When filled with appropriate donor and acceptor fluorophores, the two 
species of nanospheres can produce a new fluorescent signal by Fluorescence Resonance 
Energy Transfer (FRET) when bound close together by the CLAMPs. In this way logic gates 
such as "AND", "OR", and "NOR" can be constructed, relying upon the signal from this 
system of aptamers and nanospheres. 
Introduction 
Mesoporous silica nanospheres (MSN) provide an exciting new medium for testing the 
limits of aptamer technology. Forming spherical particles 200 nm in diameter, these 
nanospheres have 2.3 nm diameter cylindrical pores arranged hexagonally that pass entirely 
through the nanospheres (56). The cylindrical, hexagonally arranged pores give the 
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mesoporous silica nanospheres a designation ofMCM-41 type (Figure 15). These channels 
are formed during production of the nanospheres by the co-condensation method (57, 58) 
developed by Victor Lin's group. The nanospheres can be separately derivatized via several 
different chemical linking groups (Figure 16), linking ligands for the aptamers to the surface of 
the nanospheres or the inside surfaces of the pores. Various fluorophores can be contained 
inside the nanosphere material to create the different fluorescent nanospheres required for 
producing fluorescence resonance energy transfer (FRET). 
An "AND" logic gate system, designed by Victor Lin, uses different species of 
nanospheres as the inputs, with Cis-Linked Aptamers for Microanalytical Procedures 
(CLAMPs) as the mechanism for linking the nanospheres together to create the FRET output 
(Table 3). One aptamer ligand is derivatized to the surface of nanospheres containing Texas 
Red, the energy acceptor, and a second aptamer ligand is derivatized to the surface of CdS 
particles, the energy donor. When a CLAMP, containing both aptamer sequences, binds to 
both of these ligand derivatized nanoparticles, the Texas Red and CdS are brought close 
enough together for FRET to occur, resulting in a new fluorescent emission which can be 
measured as the positive output of this system. In this way, logic gates can be constructed 
that function as an optical version of the standard electronic data storage device. 
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(e) 
100nm 
Figure 15: SEM (a and b) and TEM (300kV) micrographs of the 
mesoporous silica nanospheres (c and e). The MCM-41 type of 
mesoporous channel structure of the nanospheres is visualized with the 
parallel stripes ( c) and the hexagonally packed light dots ( e) shown in 
the micrographs. The TEM micrograph ( e) was measured on 
ultramicrotomed samples with section thickness of 60-80 nm. This 
figure is modified from (56), with panels d & f removed. 
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l 
Figure 16: Synthesis of 2-(propyldisulfanyl)ethylamine 
functionalized mesoporous silica nanosphere material. 
This figure is taken from (56). 
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Table 3: AND Logic Gate System Design* 
AND Logic Gate System 
Input 1 
Input 2 
Output output hv 
*table and figures from Victor Lin 
CLAMP#l: 
Selectively bind to 
neomycin B and adenosine 
Nanosphere (A): 
CdS inside and neomycin 
B outside 
N anosphere (B): 
Texas Red inside and 
adenosine outside 
FRET from CdS to Texas 
Red gives rise to new 
emission as signal output 
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In addition to the specified goal of creating a logic gate system which may be 
applicable as an optical switch or for data storage technology, being able to link particles 
together using aptamer constructs would be useful for other applications involving aptamers. 
For instance, therapeutic molecules could be targeted to a cell type expressing a specific cell 
surface antigen for targeted drug delivery. 
Materials and Methods 
Neomycin and adenosine were purchased from Sigma. Tris base, sodium chloride, and 
magnesium chloride were purchased from Fisher Scientific. 
Nanosphere and nanoparticle synthesis. Mesoporous silica nanospheres were 
prepared by the co-condensation method (57, 58) by Daniela R. Radu. Texas Red 
nanospheres were derivatized with adenosine via an amino linkage to the C8 position of the 
adenosine molecule, as required for aptamer binding. CdS particles were linked to neomycin 
also via an amino linkage. 
RNA CLAMP preparation. See Chapter 2, Materials and Methods. 
Column affinity CLAMP binding assay. See Chapter 2, Materials and Methods. 
FRET experiments. Sonication was often used to disperse the nanospheres and CdS 
particles in solution but because this may shear the nucleic acid CLAMPs, sonication was only 
used before the addition of CLAMP. Fluorescence emission spectra were measured on a 
Fluoro Max-2 Fluorometer (ISA Jobin Yvon Spex, Horiba Group). The experimental order 
was as follows: emission spectrum of Texas Red nanospheres and CdS nanoparticles in buffer 
was measured, CLAMP sample was added, and the emission spectrum was measured again, 
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unless otherwise noted. The buffer for all FRET experiments was 50 mM Tris, 250 mM 
NaCl, 5 mM MgC12, pH 7.6 at 23°C. 
Results and Discussion 
Three CLAMPs were designed combining the neomycin and ATP RNA aptamers with 
varying linkers (Table 1 ). Neomycin-uu-ATP CLAMP 609 has the neomycin aptamer 5' with 
two uracil nucleotides as a linker before the ATP aptamer at the 3' end. ATP-uu-Neomycin 
CLAMP 610 has the ATP aptamer 5' with a two uracil nucleotide linker and the neomycin 
aptamer at the 3' end. Neomycin-lOu-ATP CLAMP 612 has the neomycin aptamer 5' with 
ten uracil nucleotides as a linker before the ATP aptamer at the 3' end. 
The binding ability of both ends of the CLAMPs were first checked by affinity column 
chromatography. Neomycin-uu-ATP CLAMP 609 binds both neomycin and ATP 
independently, with a lOmM solution of the opposite ligand unable to elute the CLAMP from 
the affinity column (Figure 17). The amount of ATP binding obtained with this CLAMP was 
later increased from the low levels seen here (see Chapter 2). The independent binding 
abilities of the ATP-uu-Neomycin CLAMP 610 and the Neomycin-lOu-ATP CLAMP 612 
were similar when tested on ATP agarose and neomycin sepharose affinity columns. 
However, simultaneous binding of both ligands was not determined. 
The emission spectra of the CLAMPs alone were checked with excitation at 360 nm to 
make sure they did not have a significant emission that would interfere with readings of the 
Texas Red emission. From the spectra ofNeomycin-uu-ATP CLAMP 609 (Figure 18a) and 
ATP-uu-Neomycin CLAMP 610 (Figure 18b) there was very little emission when compared 
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with the intensity of CdS and Texas Red emissions, especially in the 600 nm range, where the 
peak of Texas Red emission is expected ifFRET occurs. Therefore, there should be little . 
interference in the Texas Red emission spectra from the nucleic acid CLAMPs themselves. 
Changes in the Texas Red emission spectrum were first tested by measuring the 
spectrum of a solution of Texas Red nanospheres and either Neomycin-uu-ATP CLAMP 609 
or ATP-uu-Neomycin CLAMP 610, then adding CdS particles and measuring the spectrum 
again (Figure 19). The addition of CdS particles caused large changes in the emission 
spectrum, increasing the CdS emission at 400-500 nm, and also decreasing the Texas Red 
emission peak at 600 nm. This made it difficult to determine whether any FRET occurred. 
A better method for determining possible FRET is measuring the change in Texas Red 
emission with excitation at 360 nm between a solution of Texas Red nanospheres and CdS 
particles, before and after addition of CLAMP. The first results from this comparison are 
shown in Figure 20. The addition ofNeomycin-uu-ATP CLAMP 609 (225 pmol) decreased 
emission evenly all across the spectrum. This was interpreted as a dilution effect from adding 
the 30 ul of CLAMP solution to the 2 ml sample. There appeared to be no FRET produced in 
this trial. 
Another barrier to producing FRET may be balancing the amount of Texas Red 
nanospheres and CdS particles so there is enough CdS to transfer energy to the Texas Red. 
This balance was addressed in the next experiments by adjusting the relative amounts of Texas 
Red nanospheres and CdS particles until the emission peaks of each species at excitation 360 
nm were of approximately equal intensity (Figure 21 ). Then Neomycin-I Ou-ATP CLAMP 
612 was added in 3 increments and the emission spectra (excitation 360 nm) were compared 
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(Figure 22). Once again, the only change in the emission spectrum was· a drop in the intensity 
of emissions caused by dilution when the CLAMP solution was added, with no evidence of 
FRET. 
Spin column purification had been used to purify all RNA samples up to this point, and 
there was the possibility that this purification had impaired the binding ability of the CLAMPs. 
To test if this was the case, unpurified CLAMP samples were tested. The results (Figures 23 
& 24) were somewhat misleading, somewhat resembling FRET, but actually resulting from 
several different effects. The decrease in CdS particle emission over the range 400-500 nm is 
not consistent with FRET to the Texas Red nanospheres because Texas Red should only 
absorb the higher end of this range, with the maximum absorption around 560 nm. Therefore, 
this decrease in CdS emission is probably just the dilution effect from addition of CLAMP 
solution. The increase in Texas Red emission at 600 nm is harder to explain but is believed to 
be due to increased solvation of the Texas Red nanospheres caused by electrostatic 
interactions between the silica nanospheres and the high concentrations of free nucleotide 
triphosphates present in the unpurified RNA samples. This may explain why the first 20 ul 
addition ofNeomycin-IOu-ATP CLAMP 612 was the only addition that increased the Texas 
Red emission (Figure 24, aqua line) with no further increases occurring in response to the 
remaining CLAMP additions. If the maximum amount of nucleotide triphosphates had been 
bound to the nanospheres with the first addition, adding more would not increase solvation 
(and therefore, emission) any further. If this increase in emission intensity was due to 
CLAMP binding, the amount of CLAMP should be limiting, and further additions should 
increase emission intensity further. 
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Purifying all further CLAMP samples appears to be important to avoid the previous 
problems. Upon further testing with purified CLAMP samples, more odd results were seen: 
Adding any of the three CLAMPs to a Texas Red nanosphere and CdS particle mixture 
caused a decrease in CdS emission from 400-500 nm as seen previously from the dilution 
effect, but higher wavelength emissions were increased (Figures 25-27). This is most easily 
seen in Figure 20, with Neomycin-uu-ATP CLAMP 609, where 525 nm is the start of the 
increased emission intensity. With Neomycin-IOu-ATP CLAMP 612, increased emission 
intensity begins at about 480 nm (Figure 27). This increase in primarily Texas Red emission 
may be due to increased solvation like that seen with the unpurified CLAMP samples, caused 
by CLAMP molecules binding to the Texas Red nanospheres and neutralizing some of the 
silica material's hydrophobicity. In these final trials, still no FRET was observed. 
"O 
QJ .... 
::J 
w 
en 
Cl 
(.D 
0.. 
~ 
::5 u .... c 
a.J 
LI .... 
QJ 
0.. 
43 
30 
25 8 
\ 20 
tJ. 
15 \ 
/::,. 
tJ. \ 10 
8 
\ 
5 8 ' 
x-X~x 
!!,._ 8 
~ /:J.--X' -
0 0 
~ 
5 10 
Elution Fraction 
1::,.-!J. Percent Eluted (Neomycin) 
x-x Percent Eluted (ATP) 
Figure 17: Independent binding of neomycin and 
ATP by Neomycin-nu-ATP CLAMP 609. CLAMP 
was allowed to bind to either a neomycin or ATP affinity 
column, washed as normal, then washed with 5 column 
volumes of a 1 OmM solution of the opposite ligand 
(elution fractions 1-5) before elution with a lOmM 
solution of the proper ligand (elution fractions 6-15). 
Representative affinity column binding data from two 
separate trials is shown. 
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Figure 18: Emission spectra of Neomycin-nu-ATP CLAMP 609 and ATP-uu-
Neomycin CLAMP 610. With excitation at 360 run, the wavelength for exciting CdS 
particles, (a) Neomycin-uu-ATP CLAMP 609 and (b) ATP-uu-Neomycin CLAMP 610 
have very low emission at the Texas Red emission peak of 600 run. 
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Figure 19: Emission spectra ofNeomycin-uu-ATP CLAMP 609 or ATP-uu-
Neomycin CLAMP 610 and Adenosine derivatized Texas Red Nanospheres with 
and without Neomycin derivatized CdS particles. Texas Red nanospheres ((a) 2.1 
mg, (b) 2.3 mg) were sonicated in 2 ml aptamer binding buffer, then (a) Neomycin-uu-
ATP CLAMP 609 or (b) ATP-uu-Neomycin CLAMP 610 was added and emission 
spectrum was measured with excitation at 360 nm ((a) red, (b) green). CdS particles 
((a) 1.9 mg, (b) 2.4 mg) were added and the mixture sonicated before measuring new 
emission spectrum ((a) green, (b) red). 
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Figure 20: Emission spectrum of Texas Red N anospheres and CdS particles 
with and without Neomycin-nu-ATP CLAMP 609. Adenosine derivatized 
Texas Red nanospheres (5.4 mg) were mixed with neomycin derivatized CdS 
particles ( 4.4 mg) in 2 ml of aptamer binding buffer and sonicated to disperse. 
Emission spectrum was measured at excitation 360 nm (green), then Neomycin-uu-
ATP CLAMP 609 (225 pmol in 30ul) was added and emission spectrum measured 
again (red). 
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Figure 21: Balancing the CdS and Texas Red emission peaks. The 
relative amounts of CdS particles and Texas Red nanospheres were adjusted 
(green=+ blue~ red) until the two emission peaks at excitation 360 run 
were about equal (red), with 4. 5 mg CdS particles and 1. 5 mg Texas Red 
nanospheres in 2 ml of aptamer binding buffer. 
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Figure 22: Emission spectrum of Texas Red Nanospheres and CdS particles, with 
and without Neomycin-lOu-ATP CLAMP 612. Emission spectrum (excitation 360 
nm) of0.75 mg Texas Red nanospheres and 2.25 mg CdS particles in 1 ml of aptamer 
binding buffer was compared before CLAMP addition (red), with 45 pmol (50 ul) 
CLAMP (green), 90 pmol ( 100 ul) CLAMP (blue), and 117 pmol (130 ul) CLAMP 
(purple). 
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Figure 23: Emission spectrum of Texas Red N anospheres and CdS particles 
with and without unpurified (a) Neomycin-nu-ATP CLAMP 609 or (b) ATP-
uu-Neomycin CLAMP 610. Emission spectrum (excitation 351 run) of0.9 mg 
Texas Red nanospheres and 1.4 mg CdS particles in 2 ml aptamer binding buffer 
(green) was compared with the spectrum after addition of 100 ul CLAMP (red). 
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Figure 24: Emission spectrum of Texas Red Nanospheres and CdS particles 
with and without unpurified Neomycin-lOu-ATP CLAMP 612. Emission 
spectrum (excitation 351 nm) of0.9 mg Texas Red nanospheres and 1.4 mg CdS 
particles in 2 ml aptamer binding buffer (green) was compared with the spectrum after 
addition of 20 ul (aqua), 40 ul (dark purple), 60 ul (dark blue), 80 ul (light purple), 
and 100 ul (red) of CLAMP 612. 
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Figure 25: Emission spectrum of Texas Red Nanospheres and CdS particles 
with and without purified Neomycin-nu-ATP CLAMP 609. Emission spectrum 
(excitation 351 nm) of0.8 mg Texas Red nanospheres and 2.0 mg CdS particles in 2 
ml aptamer binding buffer (green) was compared with the spectrum after addition of 
600 pmol (100 ul) of purified CLAMP 609 (aqua). Excitation at 360 nm of the final 
Texas Red nanospheres, CdS particles, and CLAMP 609 mixture gave slightly higher 
emission intensities (red). 
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Figure 26: Emission spectrum of Texas Red Nanospheres and CdS particles with 
and without purified ATP-nu-Neomycin CLAMP 610. Emission spectrum (excitation 
351 nm) of0.8 mg Texas Red nanospheres and 2.0 mg CdS particles in 2 ml aptamer 
binding buffer (green) was compared with the spectrum after addition of 60 pmol (aqua), 
120 pmol (dark purple), 180 pmol (blue), 240 pmol (light purple), 300 pmol (fluoro 
green), 360 pmol (fluoro blue), 420 pmol (gray), 480 pmol (dark grey), 540 pmol (black), 
and 600 pmol (red) of purified CLAMP 610. Total volume of CLAMP solution added 
was 100 ul. 
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Figure 27: Emission spectrum of Texas Red N anospheres and CdS particles with 
and without purified Neomycin-lOu-ATP CLAMP 612. Emission spectrum 
(excitation 351 nm) of0.8 mg Texas Red nanospheres and 2.0 mg CdS particles in 2 ml 
aptamer binding buffer (green) was compared with the spectrum after addition of 160 
pmol (aqua), 320 pmol (dark purple), 480 pmol (blue), and 640 pmol (red) of purified 
CLAMP 612. Total volume of CLAMP solution added was 80 ul. 
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Conclusion 
In these early experiments, much has been learned about working with the Texas Red 
nanospheres and CdS particles in conjunction with aptamers. FRET donor:acceptor ratio 
balance was improved to maximize FRET potential. The experimental design also benefitted 
from some optimization in order to clearly determine if the CLAMPs are producing any FRET 
by binding Texas Red nanospheres and CdS nanoparticles together. Although successful 
induction of FRET was not produced, the results presented here were a vital step in 
developing this new technology. The CLAMPs are capable of binding both their ligands 
separately, so it only remains to optimize the system until both ligands can be bound 
simultaneously by the same CLAMP molecule, within the distance required to produce FRET 
from our fluorescence donor/acceptor system. 
Recommendations for Future Research 
Some issues still need to be resolved before the project can move forward. The fact 
that the nanospheres and CdS particles do not stay in suspension without constant stirring is a 
problem because stirring the mixture may hinder aptamer binding to the derivatized ligands. 
The solvation effects also make interpreting the results difficult, since this can mimic increased 
Texas Red emission that may be caused by FRET. If the nanospheres and nanoparticles can 
be made more soluble, working with this system would be easier. 
Another current unknown is the molecular weight of the nanospheres and CdS 
particles. Without this knowledge, the molar ratio of nanospheres or nanoparticles:CLAMP in 
these experiments is impossible to calculate. There are probably far more nanospheres present 
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in these experiments than CLAMP molecules, so the concentration of CLAMP may be 
severely limiting in our attempts to induce FRET. New methods are available for drastically 
increasing the amount of CLAMP transcribed, so increasing the concentration of CLAMP and 
decreasing the amount of nanospheres and CdS particles in the mixture may help balance these 
components until a noticeable FRET can be generated. 
Aminoglycosides also appear to be less than ideal ligands for this system. These 
molecules are somewhat large and difficult to chemically link at the precise location desired, 
and they bind to many different sequences of nucleic acids, which may interfere with our 
CLAMPs. The CLAMP system should be moved away from using aminoglycosides as 
ligands, to more amenable small molecules such as ATP or theophylline. 
Acknowledgement 
This project was a collaboration with Victor Lin's group in the chemistry department 
oflSU, and all the nanosphere production and characterizations are theirs, along with the 
original idea of the logic gates. Daniela R. Radu produced the derivatized Texas Red 
nanospheres and CdS particles used here, and provided the knowledge of FRET and the 
fluorophores involved to get the fluorescence emission experiments running. Victor Lin 
designed the original project parameters and provided valuable interpretations of results as 
well as helpful suggestions. I wish to thank everyone who helped us get this project off the 
ground. 
56 
CHAPTER 4: GENERAL CONCLUSIONS 
General Discussion 
Aptamers are becoming a prominent molecular tool in many different disciplines. The 
binding affinity and specificity that make these nucleic acid molecules rival antibodies allow 
aptamers to be used for many applications beyond the usefulness of antibodies. Further 
progress in developing aptamer technology will undoubtedly depend both upon specific design 
of applications for aptamers as well as basic research about their behavior. 
In Chapter 2 aminoglycosides restored ATP binding ability to an RNA aptamer within 
a CLAMP containing an additional aptamer sequence. Neomycin caused about a 2-fold 
increase in ATP binding of the CLAMPs, and tobramycin also showed a similar but smaller 
effect. CLAMPs containing either a neomycin or a theophylline aptamer in addition to the 
ATP aptamer were susceptible to this allosteric enhancement of ATP binding. 
Aminoglycosides may function as chaperones for RNA folding, potentially removing 
misfolding options from the dynamic folding equilibrium of these multiple aptamer constructs. 
This would explain the restoration of ATP binding in CLAMPs to levels consistent with the 
RNA ATP aptamer alone. 
Chapter 3 showed the preliminary results from the application of aptamers to 
developing optical logic gates. Texas Red nanospheres derivatized with adenosine and CdS 
nanoparticles derivatized with neomycin were used as a potential FRET pair, with 
Neomycin/ATP CLAMPs to link the two species of nanoparticles together. FRET was not 
produced, but the experimental system was further developed to optimize potential for FRET 
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in future experiments. This system has great potential as a proof of principle to show that 
multiple aptamer constructs may be capable of binding several nanoparticle-sized ligands 
together. When this is possible, other applications for aptamers can be developed, including 
targeted delivery of drugs to a specific site of action in a patient's body. 
Recommendations for Future Research 
There is obviously much more that can be done to elucidate the behavior of aptamers 
and develop new technologies to use them. For the study of aminoglycoside effects upon dual 
aptamer constructs, other pairs of aptamers could be tested to support the broad allosteric 
enhancement seen in these results. Ideally, both aptamers in these constructs should be tested, 
to see if aminoglycosides enhance binding at both ends of a dual aptamer construct. The 
concentration of each aminoglycoside required to produce this effect could also be more 
thoroughly examined. Other aminoglycoside molecules besides the ones studied here could 
also be tested to determine how broadly this class of molecules affects aptamer constructs. 
Much more remains to be done to develop the logic gate application of aptamer 
technology. The exact size and amount of the nanospheres still needs to be determined, and 
the ratio of CLAMP:nanosphere must be optimized. Simultaneous binding of both aptamer 
ligands must be obtained within the distance limits to produce FRET. One step that can be 
taken to simplify this first step of producing FRET will be to link a fluorescent acceptor 
molecule to a single aptamer sequence, which will then be used to bind the donor CdS 
particles. In this way, there will only be need of one aptamer to bind, and less distance 
constraints to obtain FRET. 
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